share_log
Moomoo 24/7 ·  03/06 11:51

Kura Oncology Shares Are Trading Higher After the Company Announced That It Dosed Its First Patient in Its Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology宣佈在 KO-2806 Plus 卡博贊替尼治療腎細胞癌的試驗中爲首位患者注射劑量後,該公司股價走高

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論